Cambridge Investment Research Advisors
GBT

Cambridge Investment Research Advisors’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Cambridge Investment Research Advisors’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-3,615
Closed -$246K – 3274
2022
Q3 		$246K Buy
+3,615
New +$199K ﹤0.01% 2534
2022
Q2 		– Sell
-7,387
Closed -$256K – 3269
2022
Q1 		$256K Sell
7,387
-900
-11% -$26.9K ﹤0.01% 2677
2021
Q4 		$243K Buy
+8,287
New +$257K ﹤0.01% 2719
2020
Q4 		– Sell
-6,159
Closed -$340K – 2806
2020
Q3 		$340K Buy
6,159
+370
+6% +$23.5K ﹤0.01% 1855
2020
Q2 		$365K Sell
5,789
-651
-10% -$44.7K ﹤0.01% 1738
2020
Q1 		$329K Buy
6,440
+768
+14% +$51.4K ﹤0.01% 1617
2019
Q4 		$451K Buy
5,672
+717
+14% +$42.5K ﹤0.01% 1648
2019
Q3 		$240K Buy
4,955
+200
+4% +$10.4K ﹤0.01% 1990
2019
Q2 		$250K Sell
4,755
-1,370
-22% -$78.7K ﹤0.01% 1869
2019
Q1 		$324K Sell
6,125
-205
-3% -$10.1K ﹤0.01% 1759
2018
Q4 		$260K Sell
6,330
-525
-8% -$19.7K ﹤0.01% 1754
2018
Q3 		$260K Buy
6,855
+1,555
+29% +$68.9K ﹤0.01% 1887
2018
Q2 		$240K Buy
+5,300
New +$241K ﹤0.01% 1881

Other funds holding GBT

BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Cambridge Investment Research Advisors's GBT Position: Q4 2022 in Review

Cambridge Investment Research Advisors sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2022, closing a stake of 3,615 shares — an estimated $246K sold.

Cambridge Investment Research Advisors first reported a position in GBT in Q2 2018 and held it in 13 quarters. The position peaked at $451K in Q4 2019. 2 funds tracked by Wall St. Rank hold GBT as of Q4 2022.

  • Cambridge Investment Research Advisors reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 3,615 Global Blood Therapeutics, Inc. shares in Q4 2022, an estimated $246K.
  • Cambridge Investment Research Advisors first reported a position in Global Blood Therapeutics, Inc. in Q2 2018 and held it in 13 quarters.
  • Cambridge Investment Research Advisors's Global Blood Therapeutics, Inc. position peaked at $451K in Q4 2019.
  • 2 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2022.

Based on Cambridge Investment Research Advisors's 13F filing for Q4 2022, filed 8 Feb 2023.